drugset / Trial / NCT03650582

Intranasal Glucagon and Energy Balance

NCT03650582

Phase 2/3 Unknown 20 enrolled University Health Network, Toronto
RandomizedCrossoverSingle-blindBasic science

Summary

People who are overweight often find it difficult to lose weight through diet and medications because weight loss reduces the amount of energy spent by the body and increases appetite. Glucagon, when given as an injection, reduces appetite and increases the amount of energy spent by the body, even when resting. Based on studies in animals, it does so by working on the brain. However, when gives as an injection it raises blood sugar levels by acting on the liver and therefore it is not used as a weight loss drug. It has previously been shown that hormones such as glucagon, when given as a spray through the nose, can reach the brain with no major effect on the liver. Importantly it does not increase blood sugar. In this study the research team is investigating whether nasal glucagon reduces appetite and increases energy spent by the body compared to a placebo spray. If it does, it may be a potential treatment for losing weight.

Timeline

Start
2017-06-06
Primary completion
2018-09-30
Completion
2018-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Glucagon Peptide 0.7 mg Intranasal

Indications